Table 3.

Antigenicity of HA22 and HA22-LR-8M to human antisera

Patient*	IC50 of HA22 (nM)	IC50 of HA22-LR-8M (nM)	Binding† (%)
1	0.021	97	0.022
2	0.13	>400	<0.033
3	0.56	>400	<0.14
4	2.8	140	1.9
5	9.1	>400	<2.3
6	0.35	8.3	4.2
7	0.16	0.57	28
8	0.096	0.26	37
9	0.08	0.19	42

*Patients were treated with HA22 (three to five cycles) and developed neutralizing antibodies.

^†IC₅₀ ratio (HA22/HA22-LR-8M) x 100.